What is pathophysiology of Alzheimer?

['Widikila lutiti yai']

Inki kele maladi ya Alzheimer?

Maladi ya Alzheimer kele maladi mosi ya mpasi yina ke vandaka ti mutindu ya mbi ya kubumba baproteine, ke vandaka ti maladi ya kupola, mpi ke salaka nde baselile ya butomfu kusala ve mbote.

Bikalulu zole ya ntete ya maladi ya Alzheimer kele plaques ya beta-amyloïde (Aβ) mpi ba enchevêtrement neurofibrillaire (NFT) na butomfu.

Ba plaque ya beta-amyloïde ke basikaka ntangu ba enzymes ke zengaka bitini ya proteine yina ke salaka nde ba amyloïde kubasika (APP) sambu na kusala ba peptide ya Aβ.

Peptide yai ke vukanaka mpi ke salaka fibrille yina ke vandaka ve ti masa, yina ke vukanaka na nganda ya baselile ya butomfu, yo ke bebisaka mutindu baselile ke solulaka mpi ke fwaka baselile ya butomfu.

Bantu keyindulaka nde, kuvukana ya plaque ya Aβ kele mosi na kati ya mambu ya ntete yina kebasikaka na maladi ya Alzheimer, mpi yo lenda vanda mpi na kisina ya maladi ya butomfu.

Ba tangle ya neurofibrilles ke basikaka ntangu proteine tau ke kumaka ti fosforile mingi mpi ke salaka ba filamente ya mbi na kati ya baselile ya butomfu.

Ba-tube yai ya kele ti bima mingi ya ke sadisaka nitu na kusala kisalu na yo ke salaka nde ba-neurone kusala ve mbote.

Nsukansuka, ba neurone yina kebebaka kefwaka.

Maladi ya ntu ke vandaka mpi na bupusi na maladi ya Alzheimer.

Bima yina ke taninaka nitu ke salaka mambu ntangu plake ya Aβ mpi NFT ke vukana na kubasisaka ba cytokine yina ke salaka nde maladi kuyantika, yina lenda bebisa baselile ya butomfu.

Diaka, kele ti banzikisa ya ke monisa nde basusi ya ke salaka nde nitu kukuma ti bima mingi ya ke fwaka, kubeba ya mitochondrie, mpi kubeba ya glucose ke salaka nde maladi ya Alzheimer kukuma ngolo.

Mambu yai lenda sala nde baselile ya butomfu kusala ve mbote mpi kufwa, ebuna yo lenda kumisa maladi ngolo.

Na kutuba ya mbote, maladi ya Alzheimer kele mpasi mingi sambu na mambu mingi yina kepusaka bantu na kuvidisa mayele mpi na kuvila mambu yina bo vandaka kuyindula.

['Baverse ya nkaka']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nemeroff CB: The preeminent role of neuropeptide systems in the early pathophysiology of Alzheimer disease: up with corticotropin-releasing factor, down with acetylcholine. Arch Gen Psychiatry. 1999, 56 (11): 991-2.

Skoog I, Kalaria RN, Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord. , 13 Suppl 3 (): S106-14.

Proft J, Weiss N: Jekyll and Hide: The two faces of amyloid β. Commun Integr Biol. 2012, 5 (5): 405-7.

Whitehouse PJ, Hedreen JC, White CL, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol. 1983, 13 (3): 243-8.

Casadesus G, Moreira PI, Nunomura A, Siedlak SL, Bligh-Glover W, Balraj E, Petot G, Smith MA, Perry G: Indices of metabolic dysfunction and oxidative stress. Neurochem Res. , 32 (4-5): 717-22.

Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, Vasto S: Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res. , 13 (2-3): 301-13.

Raskind MA, Peskind ER: Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord. 1994, 8 Suppl 3 (): 54-60.

Schindler SE, McConathy J, Ances BM, Diamond MI: Advances in diagnostic testing for Alzheimer disease. Mo Med. , 110 (5): 401-5.

Singh VK: Immune-activation model in Alzheimer disease. Mol Chem Neuropathol. , 28 (1-3): 105-11.

['Disclaimer: mambu ya kimunganga']

['Site Internet yai kele kaka sambu na kulonga mpi kupesa bansangu, kansi yo kele ve sambu na kupesa bandongisila ya minganga to kusadila bantu ya nkaka kisalu.']

['Bo fwete sadila ve bansangu yina bo kepesa sambu na kuzaba to kubelula maladi mosi buna, mpi bantu yina kesosa bandongisila ya kimunganga fwete solula ti munganga yina kele ti nswa ya kusala kisalu yina.']

['Tala nde, ba-apareyi yina ke pesaka bamvutu na bangiufula ke vandaka ve mbote ntangu bo ke sadilaka ntalu, mu mbandu ntalu ya bantu yina bo me zaba nde bo ke belaka maladi mosi buna.']

['Sosa ntangu yonso bandongisila ya munganga to ya muntu ya nkaka ya me zaba kisalu ya kusansa bantu sambu na maladi na nge. Kuvila ve bandongisila ya munganga to kusukinina ve na kusosa yo sambu na mambu ya nge me tanga na site Internet yai. Kana nge ke yindula nde nge kele ti maladi ya ngolo, binga 911 to kwenda nswalu na lupitalu ya me finama. Site Internet yai to mutindu nge ke sadila yo ke sala ve nde nge kuma nduku ya munganga to nkengi ya maladi.']

['Banswa ya kusonika']

['Nsiku ya Banswa ya Bansoniki ya Internet ya mvu 1998, 17 U.S.C. § 512 (DMCA) ke pesa nswa na bantu yina kele ti banswa ya bansoniki ya ke kwikila nde mambu yina ke monana na Internet ke fwa banswa na bo na nsi ya nsiku ya banswa ya bansoniki ya États-Unis. ']

['Kana nge ke mona nde mambu ya nge ke tanga na site Internet na beto to na baservice na beto ke fwa banswa na nge, nge (to muntu yina ke twadisaka nge) lenda tindila beto mukanda sambu na kulomba nde beto katula yo to kukanga nzila na nge ya kusadila yo.']

['Bo fwete tinda bansangu na mukanda na nzila ya email (tala na "Kutuba na beto" sambu na kuzaba adresi ya email).']

['Nsiku ya DMCA ke lomba nde na mukanda na nge ya ke tubila nde bo me fwa nsiku ya banswa ya bantu, nge sonika mambu yai: (1) mutindu ya kutendula kisalu yina bo me fwa nsiku; (2) mutindu ya kutendula mambu yina bo me fwa nsiku mpi bansangu yina ta sadisa beto na kuzaba kisika yina mambu yango kele; (3) bansangu ya nge lenda sadila sambu na kusolula ti nge, tanga mpi adresi na nge, nimero ya telefone mpi adresse ya e-mail; (4) mambu ya nge me tuba nde nge ke kwikila nde mambu yina nge ke tuba kele ve na nswa ya munkwa-kisalu to muntu yina me pesa nswa na yo to na nsiku ya leta.']

['5) na nima ya kupesa nzikisa na mukanda yina nge me sonika, nge fwete ndima nde mambu yina nge me tuba kele ya kieleka mpi nde nge kele ti nswa ya kusadila banswa yina bo me bebisa.']

['mpi (6) kidimbu ya muntu yina kele ti nswa ya kubasisa yo to ya muntu yina kele ti nswa ya kusala mambu na zina na yandi. ']

['Kana nge pesa ve bansangu yai yonso, yo lenda sala nde bo sala ve mambu nswalu.']

['Kusolula']

['Beno tindila beto email kana beno kele na ngyufula to ngindu.']

What is pathophysiology of alzheimer?

The pathophysiology of Alzheimer's disease (AD) is a complex process that involves the accumulation of abnormal proteins, inflammation, and neuronal dysfunction.

The two main hallmarks of AD are the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) in the brain.

Amyloid-beta plaques are formed when fragments of the amyloid precursor protein (APP) are cleaved by enzymes to form Aβ peptides.

These peptides aggregate and form insoluble fibrils that accumulate outside neurons, disrupting cell-to-cell communication and leading to neuronal death.

The accumulation of Aβ plaques is thought to be one of the earliest events in the development of AD, and it is believed to contribute to the neurodegenerative process.

Neurofibrillary tangles are formed when the protein tau becomes hyperphosphorylated and forms abnormal filaments inside neurons.

These tangles disrupt the normal functioning of the microtubules, which are essential for the transport of nutrients and other materials within the neuron.

The tangles eventually lead to the death of the affected neurons.

Inflammation also plays a role in the pathophysiology of AD.

The immune system responds to the accumulation of Aβ plaques and NFTs by releasing pro-inflammatory cytokines, which can exacerbate the damage to neurons.

Additionally, there is evidence that oxidative stress, mitochondrial dysfunction, and impaired glucose metabolism contribute to the pathophysiology of AD.

These factors can lead to neuronal dysfunction and death, further exacerbating the disease process.

Overall, the pathophysiology of AD is a complex interplay of multiple factors that ultimately lead to the progressive decline in cognitive function and memory loss that characterizes the disease.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.